



# Proteomics International

LABORATORIES LTD

TSN - ASX Gems Conference  
*Healthcare Spotlight*

Precision diagnostics: Commercial Launch

---

19 December 2025

**Dr. Richard Lipscombe**  
Managing Director

# Forward Looking Statements

---

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

Material Business Risks. The Company has identified specific risks that could impact upon its future prospects. These risks are listed in the PIQ 2025 Annual Report.

# Proteomics International Key Highlights



**Launching four  
first-in-class diagnostics  
on two continents in FY26**

PromarkerD   PromarkerEso  
PromarkerEndo   **OxiDx**



**Large addressable markets  
with significant unmet  
medical needs**



**Tests validated in large  
clinical studies**

**Significant advantages over  
current Standards-of-Care**



**Consumer driven strategy**

- Targeting Primary Care & GP Clinics
- Patient digital platform built
- Proven demand with KOLs on board



**Products developed**

**Patented**

**Highly attractive margins**



**Funded to execute  
launch strategies**

**Strategically positioned  
to secure  
Licencing Agreements**

# Problem & Solution: a suite of novel diagnostic tests

*Targeting major diseases which are currently detected late → existing outcomes are poor for patients & cost healthcare system billions of dollars*

Promarker<sub>D</sub>

Diabetic Kidney Disease

COMMERCIALISATION

- A novel and accurate blood test for predicting the onset of chronic kidney disease in type 2 and type 1 diabetes (DKD)
- Currently 1 in 2 people with diabetes will develop DKD
- DKD leads to dialysis/kidney transplant; US reimbursement price pending
- Ramp-up phase following launch in Australia and USA CY25

Promarker<sub>Endo</sub>

Endometriosis

DEVELOPMENT

COMMERCIALISATION

- First-in-class blood test identifies all stages of endometriosis with high accuracy
- Current diagnosis takes average 7 yrs and requires invasive laparoscopy
- Launch in Australia pending; USA to follow

Promarker<sub>Eso</sub>

Esophageal Cancer

COMMERCIALISATION

- A novel and accurate blood test to diagnose esophageal cancer
- Commonly caused by chronic acid reflux (or 'GERD')
- Current diagnosis requires endoscopy + biopsy
- Ramp-up phase following launch in Australia in CY25; USA pending

OxiDx

Oxidative Stress

DEVELOPMENT

COMMERCIALISATION

- Unique test precisely identifies muscle damage & assesses training recovery
- In professional sports muscle damage accounts for 55% of injuries, while 85% of racehorses get injured during their 2- & 3- year-old racing seasons
- Launch in Australia pending; USA to follow



# Market Launch: Ramp Up → Partnering

*Drive near-term revenue with maximum optionality for strategic partnering*

## ***Focus on market awareness and launch of tests***



## ***Demonstrate market adoption and sales***



## ***Grow sales via strategic partnerships***

- ✓ Developed suite of highly accurate, tests for large unmet medical needs
- ✓ Platform, analytical infrastructure & digital sales pathway built
- ✓ Enables tech transfers of each clinical test to future partners
- ✓ Provides fastest pathway to achieving product launch and revenues
- ✓ Reimbursement pricing (USA) imminent for PromarkerD – other tests to follow

- ✓ Engagement with GP clinics, KOLs & end users to refine sales practices
- ✓ Grow market awareness via traditional and digital avenues
- Increase market up-take as market awareness improves
- ✓ Attractive pre-built platform for any potential licensing partner:
  - Global virtual health and diagnostic companies
- Leverage more attractive terms for out-licensing as tests are in market

- Industry and Governments are focusing on Personalised/Precision medicine
- Healthcare and diagnostic companies actively seeking new diagnostic tests
- Ongoing dialogue with prospective strategic partners
- Company will retain optionality for its tests:
  - Drive revenue through the platform,
  - Non-exclusive licensing agreements & retain use of platform, and
  - Provide exclusive rights to licensing partners

# Milestones: multiple value drivers achieved & ahead

Milestone	TARGET QTR	FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Impact
<b>Commercial</b>							
Australian lab certified for clinical testing		✓					Basis for all Promarker tests to be run clinically
US Reference Lab established		✓					Key to first US sales and reimbursement
PromarkerD launched in W. Australia		✓					Pilot launch to optimise logistics & digital framework
PromarkerD launched across Australia			✓				Enable clinical testing in Australia and tech transfer overseas
PromarkerD launched in USA		✓					Initiate pathway to commercial sales and partnering
PromarkerEso launched in Aus/USA			✓				Initiate pathway to commercial sales and partnering
PromarkerEndo launched in Aus/USA							Initiate pathway to commercial sales and partnering
Material sales of PromarkerD							Drive future revenue
Promarker tests licensing deals							Drive regional uptake and future revenue
<b>Clinical/Technical</b>							
Promarker tests validation studies		✓					New first-in-class diagnostic tests
Promarker diagnostics pipeline updates							New diagnostic tests in development
<b>Reimbursement</b>							
PromarkerD reimbursement code granted		✓					Support US roll-out
PromarkerD US Medicare pricing set				✓			Broaden usage of test in USA
PromarkerEso PLA code application							Support US roll-out

# Corporate Overview

## Financial and Corporate

### Corporate Snapshot

ASX code	PIQ
Market Capitalisation (10 Dec 2025)	A\$67m
Cash (30 Sep 2025) + (R&D Tax Incentive \$2m & Grant \$0.5m H1 FY26)	A\$12.7m
Share Price (10 Dec 2025)	A\$0.41
Shares on issue (10 Dec 2025)	163.7m
Quarterly Cash Receipts – Q1 FY26	A\$1.8m
Quarterly Cash Burn – Q1 FY26	A\$1m


Price (\$)



Volume (M)

- **Strong Capital position**
  - \$12M capital raise completed May 2025 comprising \$4.5M Institutional & Director placement + \$7.5M oversubscribed SPP
  - Funded to execute launch strategies
- **Revenue generating**
  - Bioanalytical service business helps offset cash burn
  - Launching four key tests on two continents in FY26:
    - PromarkerD
    - PromarkerEso
    - PromarkerEndo
    - OxiDx
- **State-of-the-art laboratories**
  - Specialist proteomics technology platform
  - Cutting edge facility with world leading accreditations
  - US clinical reference laboratory established (CLIA certified)
  - Headquartered on QEII Medical Campus, Perth, WA
- **Top 40 Shareholders hold 41%**
  - Directors are highly aligned with shareholders holding 11%

# Investment Summary




Proteomics International

LABORATORIES LTD

- Commercialising x4 first-in-class blood tests for major diseases and conditions with significant unmet need
- Ramp-up phase for PromarkerD & PromarkerEso with first sales already achieved
- Commercial platform developed to drive awareness for each test in Australia and USA to attract strategic partners
- Proprietary platform technology provides engine to develop further tests
- Funding, team, infrastructure and certifications in place
- Catalyst rich Financial Year 2026





**Proteomics International**

LABORATORIES LTD

# Contact

---

## **Dr Richard Lipscombe**

### **Managing Director**

T: +61 8 9389 1992

E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

## **Dirk van Dissel**

### **Investor Relations & Corporate Advisory**

Candour Advisory

T: +61 408 326 367

E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)